KaloBios CFO, Accounting Firm Resign After Shkreli's Arrest
- Nasdaq warns shares of biotech company to be delisted
- Former CEO Shkreli has denied wrongdoing in fraud case
Martin Shkreli Case Holds Mirror to Pharma Business
This article is for subscribers only.
KaloBios Pharmaceuticals Inc. announced the resignations of interim Chief Financial Officer Christopher Thorn and accounting firm Marcum LLP, adding to the departures that have piled up since the arrest of Chief Executive Officer Martin Shkreli.
The biotech firm didn’t provide a reason for Thorn’s departure and said Marcum’s wasn’t related to accounting or reporting operations. KaloBios was also notified that the Nasdaq stock market plans to delist the company’s stock, in part because of Shkreli’s arrest on securities fraud charges related to another company. Shkreli, who was fired last week by KaloBios, has denied wrongdoing.